China’s First Medical Devices Innovation Base To Set Up In Chongqing
This article was originally published in PharmAsia News
China's Ministry of Science and Technology has reached an agreement with Chongqing municipal government to set up an independent national innovation industry base for medical devices. The facility will focus on common problems in the industry by building up a public service platform for fast innovation design, new technology development and application, as well as experimental technology standards. It will also conduct industry, national and international research. After five years, the base is targeted to achieve breakthrough in industrialized core technologies for 50 projects and realize a production value of RMB 50 billion. Chongqing has an edge in independent R&D and innovation within the digital health sector, having developed the world's first high-intensity focused ultrasound tumor therapy system and Asia's first gastrointestinal capsule endoscopy. (Click here for more - Chinese Language)
You may also be interested in...
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.